Guardian Pharmacy Services (GRDN) Expected to Release Quarterly Earnings on Thursday

Guardian Pharmacy Services (NYSE:GRDN) is anticipated to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.3146 per share and revenue of $365.76 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The business had revenue of $351.77 million during the quarter, compared to the consensus estimate of $340.45 million. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. On average, analysts expect Guardian Pharmacy Services to post $1.18 EPS for the current fiscal year and $1.33 EPS for the next fiscal year.

Guardian Pharmacy Services Price Performance

GRDN traded up $0.58 during trading on Tuesday, hitting $40.59. The company had a trading volume of 158,490 shares, compared to its average volume of 420,594. The company has a market cap of $2.02 billion, a PE ratio of 39.40, a P/E/G ratio of 2.11 and a beta of 0.03. The business has a 50-day moving average of $41.11 and a 200-day moving average of $38.05. Guardian Pharmacy Services has a 1-year low of $26.34 and a 1-year high of $48.33.

Analysts Set New Price Targets

GRDN has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research report on Sunday, October 25th. Truist Financial lifted their price target on Guardian Pharmacy Services from $47.00 to $51.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. KeyCorp initiated coverage on Guardian Pharmacy Services in a report on Tuesday, September 22nd. They issued an “overweight” rating and a $52.00 price objective for the company. Oppenheimer upped their price objective on Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Finally, Weiss Ratings downgraded Guardian Pharmacy Services from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.57.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc is a provider of pharmacy services focused primarily on residents of long-term care and other institutional healthcare settings. Through its network of pharmacies, the company supplies prescription medications and related pharmacy support to assisted living communities, skilled nursing facilities, behavioral health organizations, and other care providers.

The company’s services include medication dispensing and packaging, prescription delivery, medication management, clinical pharmacy support, and technology-enabled tools designed to help caregivers and healthcare professionals manage residents’ medication regimens.